The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections
Abstract
OBJECTIVES: Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a common cause of complicated skin and skin structure infections (cSSSIs). Increasing antibiotic resistance and significant morbidity in cSSSIs have led to a need for new effective and safe therapies. Ceftaroline fosamil, a novel parenteral cephalosporin with excellent in vitro activity against Gram-positive pathogens, including MRSA, and many Gram-negative pathogens, was evaluated as therapy for cSSSIs in a large multicentre study. The primary study objective was to determine non-inferiority [lower limit of 95% confidence interval (CI), -10%] in the clinical cure rate achieved with ceftaroline fosamil monotherapy compared with that achieved with vancomycin plus aztreonam in the clinically evaluable (CE) and modified intent-to-treat (MITT) patient populations. METHODS: Adult patients with cSSSIs requiring intravenous therapy received 600 mg of ceftaroline fosamil every 12 h or 1 g of vancomycin plus 1 g of aztreonam every 12 h for 5-14 days (randomized 1 : 1). Clinical and microbiological response, adverse events (AEs) and laboratory tests were assessed. Registration number NCT00424190 (http://clinicaltrials.gov/ct2/show/NCT00424190). RESULTS: Of 702 enrolled patients, 353 received ceftaroline fosamil and 349 received vancomycin plus aztreonam. Baseline characteristics of treatment groups were comparable. Clinical cure rates were similar for ceftaroline fosamil and vancomycin plus aztreonam in the CE (91.1%, 288/316 versus 93.3%, 280/300; 95% CI, -6.6, 2.1) and MITT (86.6%, 304/351 versus 85.6%, 297/347; 95% CI, -4.2, 6.2) populations, respectively. The clinical cure rate for MRSA cSSSIs was 95.1% (78/82) for ceftaroline fosamil and 95.2% (59/62) for vancomycin plus aztreonam. The microbiological success rate was also similar for ceftaroline fosamil and vancomycin overall, and for MRSA. The rates of AEs, serious AEs, deaths and discontinuations because of an AE were similar for ceftaroline fosamil and vancomycin plus aztreonam. The most common AEs for ceftaroline fosamil and vancomycin plus aztreonam were diarrhoea (3.4% versus 3.2%), nausea (5.7% versus 4.6%), headache (5.1% versus 3.7%) and pruritus (3.1% versus 8.4%), respectively. CONCLUSIONS: Ceftaroline fosamil achieved high clinical cure and microbiological success rates, was efficacious for cSSSIs caused by MRSA and other common cSSSI pathogens and was generally well tolerated. Ceftaroline fosamil has the potential to provide a monotherapy alternative for treatment of cSSSIs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Klevens, R. M. (2007) · JAMA · doi:10.1001/jama.298.15.1763 · Cited by 3,726
Waves of resistance: Staphylococcus aureus in the antibiotic era
Chambers, H. F., & DeLeo, F. R. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2200 · Cited by 2,718
Methicillin-Resistant S. aureus Infections among Patients in the Emergency Department
Moran, G. J., Krishnadasan, A., Gorwitz, R. J., Fosheim, G. E., McDougal, L. K., Carey, R. B., & Talan, D. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055356 · Cited by 2,285
Cited by
Methicillin-resistant Staphylococcus aureus
Lee, A. S., de Lencastre, H., Garau, J., Kluytmans, J., Malhotra-Kumar, S., Peschel, A., & Harbarth, S. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.33 · Cited by 1,556
Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection
Boucher, H. W., Wilcox, M., Talbot, G. H., Puttagunta, S., Das, A. F., & Dunne, M. W. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310480 · Cited by 432
Self-citationSartelli, M., Guirao, X., Hardcastle, T. C., Kluger, Y., Boermeester, M. A., Raşa, K., Ansaloni, L., Coccolini, F., Montravers, P., Abu-Zidan, F. M., et al. (2018) · World Journal of Emergency Surgery · doi:10.1186/s13017-018-0219-9 · Cited by 301
Lin, J. C., Fierer, J., Aung, G., Johns, S., Thomas, A., Jahng, M., Fierer, J., & Fierer, J. (2013) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-012-0449-9 · Cited by 109
Large Retrospective Evaluation of the Effectiveness and Safety of Ceftaroline Fosamil Therapy
Casapao, A. M., Davis, S. L., Barr, V. O., Klinker, K. P., Goff, D. A., Barber, K. E., Kaye, K. S., Mynatt, R. P., Molloy, L. M., Pogue, J. M., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02371-13 · Cited by 108
Metadata
- Authors
- Corey, G. R., Wilcox, M. H., Talbot, G. H., Thye, D., Friedland, D., Baculik, T., on behalf of the CANVAS 1 investigators, Mehra, P., Alpert, M., Baird, I., Klein, S., Litow, J., Marsh, P., Penn, R., Augustinsk, J., Young, D., Bunce, C., Green, D., Eyzaguirre, R., Ambasch, G., Curcio, D. J., Lopardo, G., Minguez, A. R., Oliva, M. E., Teglia, O. F., Campos, M., Gaete, P., Acuna, G., Jansen, L., Jauregui, A., Perez, C., Seas, C., Gutierrez, J., Mayorga, M., Bubnova, N. A., Goryunov, S. V., Krylov, K. M., Macheret, E. A., Novozhilov, A. A., Zhidkov, K. P., Kozlov, R. S., Florescu, I. P., Orasan, R., Trifu, V., Ockenfels, H.-M., Hermes, B., Brockmeyer, N., Dippel, E., Kujath, P., Kowalzick, L., Ulrich, J., Krasnodebski, I., Jaworski, R., Zaniewski, M., Wallner, G., Kapinska-Mrowiecka, M., Dziki, A., Motyka, M., Borschivsky, V. M., Gerych, I. D., Lukashov, S. M., & Pyptyuk, O. V.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-11-01
- Volume
- 65
- Issue
- Supplement 4
- Pages
- iv41-iv51
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W4237533259
- Cited by
- 165
- References
- 3
- FWCI
- 10.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. https://app.cochat.ai/papers/10.1093/jac/dkq254
- The paper
- Corey, G. R., Wilcox, M. H., Talbot, G. H., Thye, D., Friedland, D., Baculik, T., on behalf of the CANVAS 1 investigators, Mehra, P., Alpert, M., Baird, I., Klein, S., Litow, J., Marsh, P., Penn, R., Augustinsk, J., Young, D., Bunce, C., Green, D., Eyzaguirre, R., . . . Pyptyuk, O. V. (2010). CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkq254
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.